Skip to main content
. 2022 Oct 4;13:985191. doi: 10.3389/fgene.2022.985191

FIGURE 10.

FIGURE 10

(A–E) presents the drug effectiveness of different risk groups. (F) presents the results of RT-PCR. (A) Camptothecin; (B) Sorafenib; (C) Oxaliplatin; (D) Mitoxantrone; (E) Gemcitabine; (F) Expression of MIAT, ZFPM2-AS1 and ZFPM2-AS1 in HCC cells.